Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A randomized, controlled, double-blind, single center.Treatment cycle is 6 months,
Neoadjuvant Therapy \High Risk Prostate Cancer
OTHER: placebo|DRUG: Proxalutamide
Pathologic Complete Response Rate, The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy, up to 6months|Proportion of Subjects With Minimal Residual Disease, The proportion of subjects that have residual tumors with maximum diameter of 3 mm or less after radical prostatectomy, up to 6months
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A randomized, controlled, double-blind, single center.Treatment cycle is 6 months,